Plain-English translation of NCT07279714 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Researchers studied fisetin, a natural compound, to see if it could be safely used in people with mild cognitive impairment or mild Alzheimer's disease dementia. The trial examined how well participants tolerated the medication and whether it caused any safety concerns. This was a small pilot study designed to gather initial information before larger testing could be considered.
Current treatments for early memory loss are limited, and researchers are exploring whether natural compounds like this medication might offer a new option. This trial investigated whether this treatment could be a safe starting point for future research in people with early cognitive decline.
Participants received fisetin as part of this small pilot study focused on evaluating its safety and how well it was tolerated. The trial involved visits where researchers monitored participants for any side effects and checked their health with blood tests and other evaluations. Participants also underwent an MRI scan as part of the study protocol.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Canada
Phase
Testing effectiveness
Sponsor
Sunnybrook Health Sciences Centre
Collaborators
Sunnybrook Research Institute
Enrollment target
~5 participants
Started
January 2026
Primary completion
July 2026
Age range
60 Years and older
Last updated on clinicaltrials.gov in August 2026.